Breaking News Instant updates and real-time market news.

SFLY

Taken private

$39.44 /

+0.53 (+1.36%)

, APO

Apollo Global

$32.48 /

+0.13 (+0.40%)

15:27
04/24/19
04/24
15:27
04/24/19
15:27

Apollo Global, Cerberus siad to consider Shutterfly bids, Bloomberg reports

SFLY

Taken private

$39.44 /

+0.53 (+1.36%)

APO

Apollo Global

$32.48 /

+0.13 (+0.40%)

  • 25

    Apr

  • 02

    May

  • 15

    May

  • 11

    Jun

SFLY Taken private
$39.44 /

+0.53 (+1.36%)

02/06/19 Aegis
Shutterfly investors' 'best bet' is to hang on in hopes for deal, says Aegis
02/06/19 SunTrust
Shutterfly price target lowered to $55 from $70 at SunTrust
02/06/19 Baird
Shutterfly near-term risks elevated, says Baird
02/04/19
Fly Intel: Top five analyst initiations
APO Apollo Global
$32.48 /

+0.13 (+0.40%)

04/17/19 Oppenheimer
Oppenheimer moving to Not Rated on Smart & Final Stores
01/14/19 JPMorgan
Arconic downgraded to Neutral from Overweight at JPMorgan
11/14/18
On The Fly: Top five analyst downgrades
11/14/18 Morgan Stanley
Morgan Stanley downgrades Apollo Global and Carlyle, favors brokers late cycle

TODAY'S FREE FLY STORIES

Initiation
Vaxart initiated with a Buy at B. Riley FBR » 21:22
07/12/20
07/12
21:22
07/12/20
21:22
VXRT

Vaxart

$7.97 /

-0.21 (-2.57%)

B. Riley FBR initiated…

B. Riley FBR initiated coverage of Vaxart with a Buy rating and $22 price target.

ShowHide Related Items >><<
VXRT Vaxart
$7.97 /

-0.21 (-2.57%)

VXRT Vaxart
$7.97 /

-0.21 (-2.57%)

07/01/20 Maxim
Inovio downgraded to Hold from Buy at Maxim
06/26/20 Raymond James
Vaxart already had vaccine deals with Emergent, Kindred, notes Raymond James
04/30/20 H.C. Wainwright
Vaxart price target raised to $7 from $3 at H.C. Wainwright
08/15/19 Brookline
Vaxart initiated with a Buy at Brookline
VXRT Vaxart
$7.97 /

-0.21 (-2.57%)

VXRT Vaxart
$7.97 /

-0.21 (-2.57%)

VXRT Vaxart
$7.97 /

-0.21 (-2.57%)

Initiation
Alcobra initiated with a Buy at B. Riley FBR » 21:21
07/12/20
07/12
21:21
07/12/20
21:21
ADHD

Alcobra

$0.00 /

+ (+0.00%)

B. Riley FBR initiated…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Periodicals
Analog Devices in talks to acquire Maxim Integrated for about $20B, WSJ reports » 20:07
07/12/20
07/12
20:07
07/12/20
20:07
ADI

Analog Devices

$124.42 /

+0.14 (+0.11%)

, MXIM

Maxim Integrated

$64.10 /

-0.33 (-0.51%)

Analog Devices (ADI) is…

Analog Devices (ADI) is in talks to buy rival Maxim Integrated (MXIM) for about $20B in what would be one of the largest merger deals of the year, The Wall Street Journal's Cara Lombardo reports, citing people familiar with the matter. Analog and Maxim are discussing an all-stock deal that could be finalized as soon as Monday, the author adds. Reference Link

ShowHide Related Items >><<
MXIM Maxim Integrated
$64.10 /

-0.33 (-0.51%)

ADI Analog Devices
$124.42 /

+0.14 (+0.11%)

ADI Analog Devices
$124.42 /

+0.14 (+0.11%)

06/30/20 SunTrust
Xilinx price target raised to $104 from $93 at SunTrust
05/21/20 Raymond James
Analog Devices price target raised to $125 from $100 at Raymond James
05/21/20 SunTrust
Analog Devices price target raised to $133 from $124 at SunTrust
05/21/20 RBC Capital
Analog Devices price target raised to $130 from $122 at RBC Capital
MXIM Maxim Integrated
$64.10 /

-0.33 (-0.51%)

04/29/20 Credit Suisse
Maxim Integrated price target lowered to $60 from $68 at Credit Suisse
03/30/20 Citi
Maxim Integrated price target lowered to $52 from $65 at Citi
03/20/20
Fly Intel: Top five analyst initiations
03/20/20 Nomura Instinet
Maxim Integrated initiated with a Neutral at Nomura Instinet
MXIM Maxim Integrated
$64.10 /

-0.33 (-0.51%)

ADI Analog Devices
$124.42 /

+0.14 (+0.11%)

ADI Analog Devices
$124.42 /

+0.14 (+0.11%)

ADI Analog Devices
$124.42 /

+0.14 (+0.11%)

ADI Analog Devices
$124.42 /

+0.14 (+0.11%)

Hot Stocks
Fly Intel: Top five weekend stock stories » 19:51
07/12/20
07/12
19:51
07/12/20
19:51
FB

Facebook

$245.01 /

+0.35 (+0.14%)

, DIS

Disney

$119.33 /

+2.42 (+2.07%)

, KO

Coca-Cola

$45.15 /

+1.23 (+2.80%)

, UL

Unilever

$54.23 /

+0.535 (+1.00%)

, SBUX

Starbucks

$74.29 /

+0.69 (+0.94%)

, BP

BP

$22.46 /

+0.405 (+1.84%)

, CVX

Chevron

$85.24 /

+2.46 (+2.97%)

, COP

ConocoPhillips

$39.70 /

+1.4 (+3.66%)

, XOM

Exxon Mobil

$42.66 /

+1.315 (+3.18%)

, RDS.A

Royal Dutch Shell

$32.20 /

+0.91 (+2.91%)

, RDS.B

Royal Dutch Shell

$30.30 /

+0.815 (+2.76%)

, TOT

Total

$37.77 /

+0.59 (+1.59%)

, ASML

ASML

$396.30 /

+1.605 (+0.41%)

, NOK

Nokia

$4.13 /

-0.045 (-1.08%)

, JWN

Nordstrom

$15.75 /

+0.46 (+3.01%)

Catch up on the…

Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Facebook (FB) is considering a ban on political ads in the days before November's U.S. presidential election as a way to cut down on the viral spread of misinformation and voter suppression, Bloomberg's Kurt Wagner and Naomi Nix reporte, citing people familiar with the matter. The social media giant has been under fire for weeks from civil rights leaders for what they say is a failure by the company to properly enforce its policies around hate speech and information meant to keep voters from participating, the authors noted. 2. After closing in March because of the pandemic, Walt Disney World (DIS) began tossing confetti again at 9am on Saturday, with two of the four major parks, the Magic Kingdom and Animal Kingdom, welcoming back a limited number of temperature-checked visitors, The New York Times' Brooks Barnes reported. Epcot and Disney's Hollywood Studios were set to reopen on Wednesday, the author noted, as the coronavirus continues its rampage through Florida, with officials reporting over 15,000 new infections on Sunday. 3. In the wake of Facebook's first big scandal in 2018, Barron's labeled the company a sin stock - controversial but still full of upside, and now Facebook finds itself in the middle of a global boycott from 1,000 advertisers, brought to task by a coalition of civil-rights groups that cite hate speech and voter suppression that appear on its platform, Max Cherney wrote in this week's edition of Barron's. While most stocks would crater under that kind of pressure, Facebook is well insulated from advertiser defections, even with big brands like Coca-Cola (KO), Unilever (UL) and Starbucks (SBUX) pausing their spending given its 8M customers, mostly small and medium-sized businesses buying adds, the author notes. 4. Saudi Arabia, the world's largest oil exporter, and other major oil-producing countries are likely to increase their output in August, as coronavirus lockdowns ease and demand begins to rise again, The New York Times's Stanley Reed reported. The Organization of the Petroleum Exporting Countries, Russia and other producers are expected to modestly ease the record production cuts that they agreed to in April and later extended through July, the author notes. A committee of key officials from the OPEC and Russia will meet on Wednesday by video conference to discuss their approach to the market. Publicly traded companies in the space include BP (BP), Chevron (CVX), ConocoPhillips (COP), Exxon Mobil (XOM), Royal Dutch Shell (RDS.A) and Total (TOT). 5. Nokia (NOK), Nordstrom (JWN), and ASML (ASML) saw positive mentions in this week's edition of Barron's.

ShowHide Related Items >><<
XOM Exxon Mobil
$42.66 /

+1.315 (+3.18%)

UL Unilever
$54.23 /

+0.535 (+1.00%)

TOT Total
$37.77 /

+0.59 (+1.59%)

SBUX Starbucks
$74.29 /

+0.69 (+0.94%)

RDS.B Royal Dutch Shell
$30.30 /

+0.815 (+2.76%)

RDS.A Royal Dutch Shell
$32.20 /

+0.91 (+2.91%)

NOK Nokia
$4.13 /

-0.045 (-1.08%)

KO Coca-Cola
$45.15 /

+1.23 (+2.80%)

JWN Nordstrom
$15.75 /

+0.46 (+3.01%)

FB Facebook
$245.01 /

+0.35 (+0.14%)

DIS Disney
$119.33 /

+2.42 (+2.07%)

CVX Chevron
$85.24 /

+2.46 (+2.97%)

COP ConocoPhillips
$39.70 /

+1.4 (+3.66%)

BP BP
$22.46 /

+0.405 (+1.84%)

ASML ASML
$396.30 /

+1.605 (+0.41%)

FB Facebook
$245.01 /

+0.35 (+0.14%)

07/09/20 Wedbush
Pinterest price target raised to $31 from $26 at Wedbush
07/07/20 BofA
Potential U.S. ban of TikTok could be tailwind to Snap engagement, says BofA
07/01/20 Monness Crespi
Facebook has opportunity to emerge from crisis stronger, says Monness Crespi
07/01/20 Goldman Sachs
Facebook checks show limited impact from ad boycott, says Goldman Sachs
DIS Disney
$119.33 /

+2.42 (+2.07%)

07/10/20 JPMorgan
JPMorgan has 'increasing conviction' in Disney returning to health
07/08/20 Guggenheim
Disney price target raised to $123 from $115 at Guggenheim
06/24/20 Morgan Stanley
Morgan Stanley says time might be right for Disney to move ESPN to streaming
06/19/20 Wells Fargo
Disney price target raised to $118 from $107 at Wells Fargo
KO Coca-Cola
$45.15 /

+1.23 (+2.80%)

06/17/20 Jefferies
Nestle home-office water business would be a fit for Primo Water, says Jefferies
05/28/20 Credit Suisse
Boston Beer downgraded to Neutral on valuation at Credit Suisse
05/18/20 Guggenheim
Guggenheim raises PepsiCo to 'Best Idea' in Food and Beverage, ups target
05/11/20 Citi
Monster Beverage downgraded to Neutral from Buy at Cit
UL Unilever
$54.23 /

+0.535 (+1.00%)

07/07/20 Bryan Garnier
Unilever downgraded to Neutral from Buy at Bryan Garnier
07/06/20 RBC Capital
Unilever price target raised to EUR 34 from EUR 33 at RBC Capital
06/29/20 Barclays
Unilever price target raised to EUR 43.70 from EUR 43.10 at Barclays
06/29/20
Fly Intel: Top five analyst downgrades
SBUX Starbucks
$74.29 /

+0.69 (+0.94%)

06/24/20 JPMorgan
Starbucks price target raised to $78 from $73 at JPMorgan
06/15/20
Fly Intel: Top five analyst initiations
06/15/20 Atlantic Equities
Starbucks initiated with an Overweight at Atlantic Equities
06/11/20
Fly Intel: Top five analyst downgrades
BP BP
$22.46 /

+0.405 (+1.84%)

07/01/20 Barclays
BP price target raised to 400 GBp from 380 GBp at Barclays
07/01/20 JPMorgan
BP price target lowered to 400 GBp from 425 GBp at JPMorgan
06/17/20 UBS
BP price target lowered to 370 GBp from 400 GBp at UBS
06/15/20 UBS
BP price target lowered to 400 GBp from 410 GBp at UBS
CVX Chevron
$85.24 /

+2.46 (+2.97%)

06/10/20
Fly Intel: Top five analyst downgrades
06/10/20
Chevron cut to Underperform at RBC Capital on valuation
06/10/20 RBC Capital
Chevron downgraded to Underperform from Sector Perform at RBC Capital
06/09/20
BofA moves 'up the risk curve' in oil, upgrades Occidental, downgrades Chevron
COP ConocoPhillips
$39.70 /

+1.4 (+3.66%)

06/19/20 Mizuho
ConocoPhillips price target raised to $46 from $37 at Mizuho
06/12/20 Jefferies
Jefferies reinstates ConocoPhillips at Buy with $56 price target
06/12/20 Jefferies
ConocoPhillips reinstated with a Buy at Jefferies
05/21/20 Mizuho
ConocoPhillips price target raised to $37 from $33 at Mizuho
XOM Exxon Mobil
$42.66 /

+1.315 (+3.18%)

06/09/20 Standpoint Research
Exxon Mobil downgraded to Hold from Buy at Standpoint Research
06/09/20 JPMorgan
Exxon Mobil price target raised to $51 from $44 at JPMorgan
05/13/20 Redburn
Exxon Mobil upgraded to Neutral from Sell at Redburn
05/04/20 Credit Suisse
Exxon Mobil price target raised to $45 from $37 at Credit Suisse
RDS.A Royal Dutch Shell
$32.20 /

+0.91 (+2.91%)

06/15/20 UBS
Royal Dutch Shell price target raised to 1,750 GBp from 1,650 GBp at UBS
05/13/20 Redburn
Royal Dutch Shell upgraded to Neutral from Sell at Redburn
05/04/20 UBS
Royal Dutch Shell price target lowered to 1,700 GBp from 1,800 GBp at UBS
05/01/20 Citi
Citi cuts Royal Dutch Shell price target 11% to GBp 1180
RDS.B Royal Dutch Shell
$30.30 /

+0.815 (+2.76%)

06/04/20 RBC Capital
Royal Dutch Shell price target raised to 2,000 GBp from 1,800 GBp at RBC Capital
05/04/20 UBS
Royal Dutch Shell price target lowered to 1,700 GBp from 1,800 GBp at UBS
04/21/20 JPMorgan
Royal Dutch Shell price target lowered to 1,650 GBp from 1,750 GBp at JPMorgan
TOT Total
$37.77 /

+0.59 (+1.59%)

06/15/20 UBS
Total price target lowered to EUR 44 from EUR 45 at UBS
06/02/20 Wolfe Research
Total downgraded to Peer Perform from Outperform at Wolfe Research
05/15/20 JPMorgan
JPMorgan replaces BP with Total on European Analyst Focus List
05/13/20 Redburn
Total upgraded to Buy from Neutral at Redburn
ASML ASML
$396.30 /

+1.605 (+0.41%)

07/10/20 JPMorgan
ASML price target raised to EUR 408 from EUR 280 at JPMorgan
07/10/20 Morgan Stanley
ASML price target raised to EUR 380 from EUR 275 at Morgan Stanley
07/09/20 Wells Fargo
ASML price target raised to $430 from $410 at Wells Fargo
06/17/20 Evercore ISI
ASML price target raised to EUR 375 from EUR 325 at Evercore ISI
NOK Nokia
$4.13 /

-0.045 (-1.08%)

07/08/20 JPMorgan
Nokia downgraded to Neutral from Overweight at JPMorgan
07/06/20 Rosenblatt
Samsung on track to replace Nokia as 5G RAN supplier at Verizon, says Rosenblatt
06/25/20 Deutsche Bank
Nokia price target raised to EUR 4.80 from EUR 4 at Deutsche Bank
06/01/20 JPMorgan
JPMorgan upgrades Nokia to Overweight with 5G cycle 'just starting'
JWN Nordstrom
$15.75 /

+0.46 (+3.01%)

05/14/20 KeyBanc
Farfetch, Nordstrom, Revolve could be impacted by Amazon offering, says KeyBanc
05/07/20 Deutsche Bank
Nordstrom price target lowered to $18 from $35 at Deutsche Bank
04/30/20 Wedbush
Nordstrom price target lowered to $20 from $36 at Wedbush
03/27/20 Cleveland Research
Nordstrom downgraded at Cleveland Research, says QTD net sales have slowed
XOM Exxon Mobil
$42.66 /

+1.315 (+3.18%)

TOT Total
$37.77 /

+0.59 (+1.59%)

SBUX Starbucks
$74.29 /

+0.69 (+0.94%)

RDS.A Royal Dutch Shell
$32.20 /

+0.91 (+2.91%)

NOK Nokia
$4.13 /

-0.045 (-1.08%)

KO Coca-Cola
$45.15 /

+1.23 (+2.80%)

JWN Nordstrom
$15.75 /

+0.46 (+3.01%)

FB Facebook
$245.01 /

+0.35 (+0.14%)

DIS Disney
$119.33 /

+2.42 (+2.07%)

CVX Chevron
$85.24 /

+2.46 (+2.97%)

COP ConocoPhillips
$39.70 /

+1.4 (+3.66%)

BP BP
$22.46 /

+0.405 (+1.84%)

ASML ASML
$396.30 /

+1.605 (+0.41%)

XOM Exxon Mobil
$42.66 /

+1.315 (+3.18%)

UL Unilever
$54.23 /

+0.535 (+1.00%)

TOT Total
$37.77 /

+0.59 (+1.59%)

SBUX Starbucks
$74.29 /

+0.69 (+0.94%)

RDS.B Royal Dutch Shell
$30.30 /

+0.815 (+2.76%)

RDS.A Royal Dutch Shell
$32.20 /

+0.91 (+2.91%)

NOK Nokia
$4.13 /

-0.045 (-1.08%)

KO Coca-Cola
$45.15 /

+1.23 (+2.80%)

JWN Nordstrom
$15.75 /

+0.46 (+3.01%)

FB Facebook
$245.01 /

+0.35 (+0.14%)

DIS Disney
$119.33 /

+2.42 (+2.07%)

CVX Chevron
$85.24 /

+2.46 (+2.97%)

COP ConocoPhillips
$39.70 /

+1.4 (+3.66%)

BP BP
$22.46 /

+0.405 (+1.84%)

ASML ASML
$396.30 /

+1.605 (+0.41%)

XOM Exxon Mobil
$42.66 /

+1.315 (+3.18%)

UL Unilever
$54.23 /

+0.535 (+1.00%)

TOT Total
$37.77 /

+0.59 (+1.59%)

RDS.A Royal Dutch Shell
$32.20 /

+0.91 (+2.91%)

NOK Nokia
$4.13 /

-0.045 (-1.08%)

KO Coca-Cola
$45.15 /

+1.23 (+2.80%)

JWN Nordstrom
$15.75 /

+0.46 (+3.01%)

FB Facebook
$245.01 /

+0.35 (+0.14%)

DIS Disney
$119.33 /

+2.42 (+2.07%)

CVX Chevron
$85.24 /

+2.46 (+2.97%)

COP ConocoPhillips
$39.70 /

+1.4 (+3.66%)

BP BP
$22.46 /

+0.405 (+1.84%)

ASML ASML
$396.30 /

+1.605 (+0.41%)

XOM Exxon Mobil
$42.66 /

+1.315 (+3.18%)

TOT Total
$37.77 /

+0.59 (+1.59%)

SBUX Starbucks
$74.29 /

+0.69 (+0.94%)

NOK Nokia
$4.13 /

-0.045 (-1.08%)

KO Coca-Cola
$45.15 /

+1.23 (+2.80%)

JWN Nordstrom
$15.75 /

+0.46 (+3.01%)

FB Facebook
$245.01 /

+0.35 (+0.14%)

DIS Disney
$119.33 /

+2.42 (+2.07%)

CVX Chevron
$85.24 /

+2.46 (+2.97%)

COP ConocoPhillips
$39.70 /

+1.4 (+3.66%)

BP BP
$22.46 /

+0.405 (+1.84%)

Periodicals
Facebook considering political ad ban for election, Bloomberg reports » 19:43
07/12/20
07/12
19:43
07/12/20
19:43
FB

Facebook

$245.01 /

+0.35 (+0.14%)

Facebook is considering a…

Facebook is considering a ban on political ads in the days before November's U.S. presidential election as a way to cut down on the viral spread of misinformation and voter suppression, Bloomberg's Kurt Wagner and Naomi Nix report, citing people familiar with the matter. The social media giant has been under fire for weeks from civil rights leaders for what they say is a failure by the company to properly enforce its policies around hate speech and information meant to keep voters from participating, hhe authors note. Reference Link

ShowHide Related Items >><<
FB Facebook
$245.01 /

+0.35 (+0.14%)

FB Facebook
$245.01 /

+0.35 (+0.14%)

07/09/20 Wedbush
Pinterest price target raised to $31 from $26 at Wedbush
07/07/20 BofA
Potential U.S. ban of TikTok could be tailwind to Snap engagement, says BofA
07/01/20 Monness Crespi
Facebook has opportunity to emerge from crisis stronger, says Monness Crespi
07/01/20 Goldman Sachs
Facebook checks show limited impact from ad boycott, says Goldman Sachs
FB Facebook
$245.01 /

+0.35 (+0.14%)

FB Facebook
$245.01 /

+0.35 (+0.14%)

FB Facebook
$245.01 /

+0.35 (+0.14%)

FB Facebook
$245.01 /

+0.35 (+0.14%)

Initiation
Royalty Pharma initiated with a Neutral at Goldman Sachs » 19:39
07/12/20
07/12
19:39
07/12/20
19:39
RPRX

Royalty Pharma

$47.55 /

-0.8 (-1.65%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
  • 16
    Jun
RPRX Royalty Pharma
$47.55 /

-0.8 (-1.65%)

RPRX Royalty Pharma
$47.55 /

-0.8 (-1.65%)

Recommendations
Walmart/Target e-comm growth not seen coming at Amazon's expense, says Jefferies » 19:37
07/12/20
07/12
19:37
07/12/20
19:37
AMZN

Amazon.com

$3,204.06 /

+19.57 (+0.61%)

, WMT

Walmart

$130.75 /

+2.99 (+2.34%)

, TGT

Target

$118.88 /

+0.98 (+0.83%)

, EBAY

eBay

$59.28 /

+0.05 (+0.08%)

After hosting a retail…

After hosting a retail and e-commerce expert, Jefferies analyst Brent Thill points out that Amazon (AMZN) seems to be the best e-commerce marketplace to build a brand, recent sales on Amazon remain robust, and the company's advertising is well positioned for continued growth. Among other highlights from the call, the analyst notes that eBay (EBAY) doesn't appear to be a share gainer, 2020 retail sales should fall 10.5% in 2020 with e-commerce growing 18%, Walmart (WMT) and Target (TGT) are the fastest growers in e-commerce right now, but growth is not coming at Amazon's expense, and Amazon is driving 43% of total e-commerce growth in 2020.

ShowHide Related Items >><<
WMT Walmart
$130.75 /

+2.99 (+2.34%)

TGT Target
$118.88 /

+0.98 (+0.83%)

EBAY eBay
$59.28 /

+0.05 (+0.08%)

AMZN Amazon.com
$3,204.06 /

+19.57 (+0.61%)

AMZN Amazon.com
$3,204.06 /

+19.57 (+0.61%)

07/10/20 Citi
Amazon.com price target raised to $3,550 from $2,700 at Citi
07/09/20 Wedbush
Pinterest price target raised to $31 from $26 at Wedbush
07/09/20 Credit Suisse
Consumer survey highlights good initial interest in Walmart+, says Credit Suisse
07/08/20 Morgan Stanley
Walmart membership plan seems geared at protecting grocery, says Morgan Stanley
WMT Walmart
$130.75 /

+2.99 (+2.34%)

07/10/20 Morgan Stanley
Walmart 'a sleeping giant to watch' in healthcare, says Morgan Stanley
07/09/20 Craig-Hallum
Craig-Hallum remains bullish on eHealth as Walmart helps validate opportunity
07/09/20 KeyBanc
Walmart+ to drive wallet share gains on grocery delivery potential, says KeyBanc
TGT Target
$118.88 /

+0.98 (+0.83%)

06/24/20 B. Riley FBR
Hanesbrands products largely sold out at Walmart and Target, says B. Riley FBR
06/19/20 Cleveland Research
Target upgraded to Buy from Neutral at Cleveland Research
05/21/20 Deutsche Bank
Target price target raised to $131 from $121 at Deutsche Bank
05/21/20 Nomura Instinet
Target price target raised to $135 from $121 at Nomura Instinet
EBAY eBay
$59.28 /

+0.05 (+0.08%)

07/10/20 B. Riley FBR
RealReal price target raised to $13 from $7 at B. Riley FBR
06/30/20 Baird
eBay price target raised to $60 from $59 at Baird
06/26/20
Fly Intel: Top five analyst upgrades
06/26/20 SunTrust
eBay price target raised to $54 from $50 at SunTrust
WMT Walmart
$130.75 /

+2.99 (+2.34%)

TGT Target
$118.88 /

+0.98 (+0.83%)

EBAY eBay
$59.28 /

+0.05 (+0.08%)

AMZN Amazon.com
$3,204.06 /

+19.57 (+0.61%)

WMT Walmart
$130.75 /

+2.99 (+2.34%)

TGT Target
$118.88 /

+0.98 (+0.83%)

EBAY eBay
$59.28 /

+0.05 (+0.08%)

AMZN Amazon.com
$3,204.06 /

+19.57 (+0.61%)

WMT Walmart
$130.75 /

+2.99 (+2.34%)

TGT Target
$118.88 /

+0.98 (+0.83%)

EBAY eBay
$59.28 /

+0.05 (+0.08%)

AMZN Amazon.com
$3,204.06 /

+19.57 (+0.61%)

WMT Walmart
$130.75 /

+2.99 (+2.34%)

TGT Target
$118.88 /

+0.98 (+0.83%)

EBAY eBay
$59.28 /

+0.05 (+0.08%)

AMZN Amazon.com
$3,204.06 /

+19.57 (+0.61%)

AMZN Amazon.com
$3,204.06 /

+19.57 (+0.61%)

Recommendations
Stifel likes near-term setup for SmileDirectClub, ups price target to $11 » 19:30
07/12/20
07/12
19:30
07/12/20
19:30
SDC

SmileDirectClub

$8.24 /

+0.18 (+2.23%)

Stifel analyst Jonathan…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SDC SmileDirectClub
$8.24 /

+0.18 (+2.23%)

SDC SmileDirectClub
$8.24 /

+0.18 (+2.23%)

06/25/20
Fly Intel: Top five analyst initiations
06/25/20 Stephens
Stephens starts SmileDirectClub at Overweight with $11 price target
06/24/20 Stephens
SmileDirectClub initiated with an Overweight at Stephens
05/14/20
Fly Intel: Top five analyst downgrades
SDC SmileDirectClub
$8.24 /

+0.18 (+2.23%)

  • 12
    Sep
SDC SmileDirectClub
$8.24 /

+0.18 (+2.23%)

SDC SmileDirectClub
$8.24 /

+0.18 (+2.23%)

SDC SmileDirectClub
$8.24 /

+0.18 (+2.23%)

Periodicals
Disney World opens gates as COVID numbers rise, NY Times » 18:05
07/12/20
07/12
18:05
07/12/20
18:05
DIS

Disney

$119.33 /

+2.42 (+2.07%)

After closing in March…

After closing in March because of the pandemic, Walt Disney World began tossing confetti again at 9am on Saturday, with two of the four major parks, the Magic Kingdom and Animal Kingdom, welcoming back a limited number of temperature-checked visitors, The New York Times' Brooks Barnes reports. Epcot and Disney's Hollywood Studios were set to reopen on Wednesday, the author notes, as the coronavirus continues its rampage through Florida, with officials reporting over 15,000 new infections on Sunday. Reference Link

ShowHide Related Items >><<
DIS Disney
$119.33 /

+2.42 (+2.07%)

DIS Disney
$119.33 /

+2.42 (+2.07%)

07/10/20 JPMorgan
JPMorgan has 'increasing conviction' in Disney returning to health
07/08/20 Guggenheim
Disney price target raised to $123 from $115 at Guggenheim
06/24/20 Morgan Stanley
Morgan Stanley says time might be right for Disney to move ESPN to streaming
06/19/20 Wells Fargo
Disney price target raised to $118 from $107 at Wells Fargo
DIS Disney
$119.33 /

+2.42 (+2.07%)

DIS Disney
$119.33 /

+2.42 (+2.07%)

DIS Disney
$119.33 /

+2.42 (+2.07%)

DIS Disney
$119.33 /

+2.42 (+2.07%)

Periodicals
Tesla shaves $3,000 off Model Y price, Bloomberg reports » 17:58
07/12/20
07/12
17:58
07/12/20
17:58
TSLA

Tesla

$1,547.54 /

+153.99 (+11.05%)

Tesla has cut the price…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TSLA Tesla
$1,547.54 /

+153.99 (+11.05%)

TSLA Tesla
$1,547.54 /

+153.99 (+11.05%)

07/09/20 Wedbush
China growth story worth $400/share in a bull case to Tesla, says Wedbush
07/07/20 Morgan Stanley
Morgan Stanley raises Tesla price target to $740 with new bull case of $2,070
07/07/20 Barclays
Tesla bears should 'remain in the shelter,' says Barclays
07/06/20 JMP Securities
Tesla price target raised to $1,500 from $1,050 at JMP Securities
TSLA Tesla
$1,547.54 /

+153.99 (+11.05%)

  • 14
    Feb
TSLA Tesla
$1,547.54 /

+153.99 (+11.05%)

TSLA Tesla
$1,547.54 /

+153.99 (+11.05%)

TSLA Tesla
$1,547.54 /

+153.99 (+11.05%)

TSLA Tesla
$1,547.54 /

+153.99 (+11.05%)

Periodicals
Chairman says WeWork set to have positive cash flow in 2021, FT reports » 17:53
07/12/20
07/12
17:53
07/12/20
17:53
WE

We Company

$0.00 /

+ (+0.00%)

, SFTBY

SoftBank

$0.00 /

+ (+0.00%)

WeWork (WE) is on track…

WeWork (WE) is on track to have positive cash flow in 2021, a year ahead of schedule, after it cut its workforce by more than 8,000 people, renegotiated leases and sold off assets, Financial Times' Arash Massoudi, Kana Inagaki and Eric Platt report, citing its executive chairman. Marcelo Claure said in an interview that the SoftBank-backed (SFTBY) office space provider had seen strong demand for its flexible work spaces since the start of the coronavirus pandemic. Reference Link

ShowHide Related Items >><<
WE We Company
$0.00 /

+ (+0.00%)

SFTBY SoftBank
$0.00 /

+ (+0.00%)

WE We Company
$0.00 /

+ (+0.00%)

10/25/19 Jefferies
SoftBank downgraded to Hold from Buy at Jefferies
09/10/19
We Company IPO is 'full speed ahead,' CNBC reports
SFTBY SoftBank
$0.00 /

+ (+0.00%)

07/10/20 Nomura Instinet
SoftBank price target raised to 7,240 yen from 6,640 yen at Nomura Instinet
05/26/20 Citi
SoftBank price target lowered to 7,100 yen from 8,200 yen at Citi
03/24/20 Jefferies
SoftBank upgraded to Buy from Hold at Jefferies
02/13/20 HSBC
SoftBank price target raised to 7,000 yen after Sprint deal approval
WE We Company
$0.00 /

+ (+0.00%)

SFTBY SoftBank
$0.00 /

+ (+0.00%)

SFTBY SoftBank
$0.00 /

+ (+0.00%)

Periodicals
Credit Suisse could cut 'hundreds' of jobs, Bloomberg reports » 17:27
07/12/20
07/12
17:27
07/12/20
17:27
CS

Credit Suisse

$10.58 /

+0.34 (+3.32%)

Credit Suisse could cut…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CS Credit Suisse
$10.58 /

+0.34 (+3.32%)

CS Credit Suisse
$10.58 /

+0.34 (+3.32%)

07/09/20 JPMorgan
Credit Suisse price target raised to CHF 11.80 from CHF 11 at JPMorgan
07/08/20 Morgan Stanley
Credit Suisse price target raised to CHF 12 from CHF 11 at Morgan Stanley
07/07/20 UBS
Credit Suisse downgraded to Neutral from Buy at UBS
06/26/20 Deutsche Bank
Credit Suisse named short-term investment idea at Deutsche Bank
CS Credit Suisse
$10.58 /

+0.34 (+3.32%)

CS Credit Suisse
$10.58 /

+0.34 (+3.32%)

CS Credit Suisse
$10.58 /

+0.34 (+3.32%)

CS Credit Suisse
$10.58 /

+0.34 (+3.32%)

Periodicals
OPEC, Russia may ease oil production cuts, NY Times reports » 17:24
07/12/20
07/12
17:24
07/12/20
17:24
BP

BP

$22.46 /

+0.405 (+1.84%)

, COP

ConocoPhillips

$39.70 /

+1.4 (+3.66%)

, TOT

Total

$37.77 /

+0.59 (+1.59%)

, XOM

Exxon Mobil

$42.66 /

+1.315 (+3.18%)

, CVX

Chevron

$85.24 /

+2.46 (+2.97%)

, RDS.A

Royal Dutch Shell

$32.20 /

+0.91 (+2.91%)

Saudi Arabia, the…

Saudi Arabia, the world's largest oil exporter, and other major oil-producing countries are likely to increase their output in August, as coronavirus lockdowns ease and demand begins to rise again, The New York Times's Stanley Reed reports. The Organization of the Petroleum Exporting Countries, Russia and other producers are expected to modestly ease the record production cuts that they agreed to in April and later extended through July, the author notes. A committee of key officials from the OPEC and Russia will meet on Wednesday by video conference to discuss their approach to the market. Publicly traded companies in the space include BP (BP), Chevron (CVX), ConocoPhillips (COP), Exxon Mobil (XOM), Royal Dutch Shell (RDS.A) and Total (TOT).Reference Link

ShowHide Related Items >><<
XOM Exxon Mobil
$42.66 /

+1.315 (+3.18%)

TOT Total
$37.77 /

+0.59 (+1.59%)

RDS.A Royal Dutch Shell
$32.20 /

+0.91 (+2.91%)

CVX Chevron
$85.24 /

+2.46 (+2.97%)

COP ConocoPhillips
$39.70 /

+1.4 (+3.66%)

BP BP
$22.46 /

+0.405 (+1.84%)

BP BP
$22.46 /

+0.405 (+1.84%)

07/01/20 Barclays
BP price target raised to 400 GBp from 380 GBp at Barclays
07/01/20 JPMorgan
BP price target lowered to 400 GBp from 425 GBp at JPMorgan
06/17/20 UBS
BP price target lowered to 370 GBp from 400 GBp at UBS
06/15/20 UBS
BP price target lowered to 400 GBp from 410 GBp at UBS
COP ConocoPhillips
$39.70 /

+1.4 (+3.66%)

06/19/20 Mizuho
ConocoPhillips price target raised to $46 from $37 at Mizuho
06/12/20 Jefferies
Jefferies reinstates ConocoPhillips at Buy with $56 price target
06/12/20 Jefferies
ConocoPhillips reinstated with a Buy at Jefferies
05/21/20 Mizuho
ConocoPhillips price target raised to $37 from $33 at Mizuho
TOT Total
$37.77 /

+0.59 (+1.59%)

06/15/20 UBS
Total price target lowered to EUR 44 from EUR 45 at UBS
06/02/20 Wolfe Research
Total downgraded to Peer Perform from Outperform at Wolfe Research
05/15/20 JPMorgan
JPMorgan replaces BP with Total on European Analyst Focus List
05/13/20 Redburn
Total upgraded to Buy from Neutral at Redburn
XOM Exxon Mobil
$42.66 /

+1.315 (+3.18%)

06/09/20 Standpoint Research
Exxon Mobil downgraded to Hold from Buy at Standpoint Research
06/09/20 JPMorgan
Exxon Mobil price target raised to $51 from $44 at JPMorgan
05/13/20 Redburn
Exxon Mobil upgraded to Neutral from Sell at Redburn
05/04/20 Credit Suisse
Exxon Mobil price target raised to $45 from $37 at Credit Suisse
CVX Chevron
$85.24 /

+2.46 (+2.97%)

06/10/20
Fly Intel: Top five analyst downgrades
06/10/20
Chevron cut to Underperform at RBC Capital on valuation
06/10/20 RBC Capital
Chevron downgraded to Underperform from Sector Perform at RBC Capital
06/09/20
BofA moves 'up the risk curve' in oil, upgrades Occidental, downgrades Chevron
RDS.A Royal Dutch Shell
$32.20 /

+0.91 (+2.91%)

06/15/20 UBS
Royal Dutch Shell price target raised to 1,750 GBp from 1,650 GBp at UBS
05/13/20 Redburn
Royal Dutch Shell upgraded to Neutral from Sell at Redburn
05/04/20 UBS
Royal Dutch Shell price target lowered to 1,700 GBp from 1,800 GBp at UBS
05/01/20 Citi
Citi cuts Royal Dutch Shell price target 11% to GBp 1180
XOM Exxon Mobil
$42.66 /

+1.315 (+3.18%)

TOT Total
$37.77 /

+0.59 (+1.59%)

RDS.A Royal Dutch Shell
$32.20 /

+0.91 (+2.91%)

CVX Chevron
$85.24 /

+2.46 (+2.97%)

COP ConocoPhillips
$39.70 /

+1.4 (+3.66%)

BP BP
$22.46 /

+0.405 (+1.84%)

XOM Exxon Mobil
$42.66 /

+1.315 (+3.18%)

TOT Total
$37.77 /

+0.59 (+1.59%)

RDS.A Royal Dutch Shell
$32.20 /

+0.91 (+2.91%)

CVX Chevron
$85.24 /

+2.46 (+2.97%)

COP ConocoPhillips
$39.70 /

+1.4 (+3.66%)

BP BP
$22.46 /

+0.405 (+1.84%)

XOM Exxon Mobil
$42.66 /

+1.315 (+3.18%)

TOT Total
$37.77 /

+0.59 (+1.59%)

RDS.A Royal Dutch Shell
$32.20 /

+0.91 (+2.91%)

CVX Chevron
$85.24 /

+2.46 (+2.97%)

COP ConocoPhillips
$39.70 /

+1.4 (+3.66%)

BP BP
$22.46 /

+0.405 (+1.84%)

XOM Exxon Mobil
$42.66 /

+1.315 (+3.18%)

TOT Total
$37.77 /

+0.59 (+1.59%)

CVX Chevron
$85.24 /

+2.46 (+2.97%)

COP ConocoPhillips
$39.70 /

+1.4 (+3.66%)

BP BP
$22.46 /

+0.405 (+1.84%)

Periodicals
Ubisoft probing harassment allegations as executives step down, WSJ reports » 17:19
07/12/20
07/12
17:19
07/12/20
17:19
UBSFY

Ubisoft

$0.00 /

+ (+0.00%)

Ubisoft said two more…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
UBSFY Ubisoft
$0.00 /

+ (+0.00%)

UBSFY Ubisoft
$0.00 /

+ (+0.00%)

07/08/20 Morgan Stanley
Ubisoft price target raised to EUR 90 from EUR 80 at Morgan Stanley
07/07/20 Barclays
Ubisoft price target raised to EUR 76 from EUR 66 at Barclays
06/16/20 Stifel
Ubisoft initiated with a Buy at Stifel
05/19/20 Berenberg
Ubisoft price target lowered to EUR 80 from EUR 81 at Berenberg
UBSFY Ubisoft
$0.00 /

+ (+0.00%)

UBSFY Ubisoft
$0.00 /

+ (+0.00%)

UBSFY Ubisoft
$0.00 /

+ (+0.00%)

Periodicals
ESPN suspends high-profile NBA reporter after profane email to Senator, WSJ says » 17:12
07/12/20
07/12
17:12
07/12/20
17:12
DIS

Disney

$119.33 /

+2.42 (+2.07%)

Walt Disney's ESPN…

Walt Disney's ESPN has suspended Adrian Wojnarowski, its top scoopmonger on the inner workings of the National Basketball Association, after it was revealed he used profane language in an email to a U.S. senator, The Wall Street Journal's Benjamin Mullin reports, citing people familiar with the matter. Wojnarowski will be suspended from ESPN for at least a week without pay, the person said. Reference Link

ShowHide Related Items >><<
DIS Disney
$119.33 /

+2.42 (+2.07%)

DIS Disney
$119.33 /

+2.42 (+2.07%)

07/10/20 JPMorgan
JPMorgan has 'increasing conviction' in Disney returning to health
07/08/20 Guggenheim
Disney price target raised to $123 from $115 at Guggenheim
06/24/20 Morgan Stanley
Morgan Stanley says time might be right for Disney to move ESPN to streaming
06/19/20 Wells Fargo
Disney price target raised to $118 from $107 at Wells Fargo
DIS Disney
$119.33 /

+2.42 (+2.07%)

DIS Disney
$119.33 /

+2.42 (+2.07%)

DIS Disney
$119.33 /

+2.42 (+2.07%)

DIS Disney
$119.33 /

+2.42 (+2.07%)

Hot Stocks
Spark announces updated data on SPK-8011 from Phase 1/2 trial in Hemophilia A » 16:51
07/12/20
07/12
16:51
07/12/20
16:51
RHHBY

Roche

$0.00 /

+ (+0.00%)

Spark Therapeutics, a…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

07/03/20 AlphaValue
Roche upgraded to Add from Reduce at AlphaValue
06/29/20 Piper Sandler
Herceptin/Perjecta approval another win for Halozyme, says Piper
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

Hot Stocks
Amag Pharmaceuticals announces presentation of ciraparantag data » 16:46
07/12/20
07/12
16:46
07/12/20
16:46
AMAG

Amag Pharmaceuticals

$7.27 /

+0.21 (+2.97%)

Amag Pharmaceuticals…

Amag Pharmaceuticals announced the poster presentation of data from two Phase 2 randomized, placebo-controlled, dose ranging studies which showed safety and efficacy of ciraparantag reversing the effects of apixaban and rivaroxaban in healthy adults age 50-75 years. Ciraparantag is in development for use in patients treated with direct oral anticoagulants and low molecular weight heparin when reversal of the anticoagulant effect of these products is needed for emergency surgery, urgent procedures or due to life-threatening or uncontrolled bleeding. Results from both studies, which randomized a total of 113 subjects, showed that steady-state anticoagulation induced by apixaban or rivaroxaban was reversed by a single IV infusion of ciraparantag in a dose-related manner as assessed by whole blood clotting time. WBCT is a direct measure of anticoagulation/hemostasis and a global measure of clotting. Mean WBCT values in the ciraparantag groups decreased toward baseline 15 minutes after dosing, versus placebo which took five hours commensurate with the decline of anticoagulant drug concentration. For reversal, defined as achieving a WBCT less than or equal to10% above baseline within one hour after dosing and subsequently sustained through at least five hours, this response was achieved in 100% of subjects receiving ciraparantag doses greater than or equal to 60 mg for reversal of apixaban, and 100% of subjects receiving ciraparantag doses of 180 mg for reversal of rivaroxaban. Ciraparantag was well tolerated at all doses evaluated in these studies. The most frequent adverse events associated with ciraparantag were mild, transient sensations of warmth or flushing, which were observed more frequently with higher doses of ciraparantag. In the two studies, adult subjects were treated with apixaban or rivaroxaban and those who reached steady-state anticoagulation were randomized within each dose cohort in a 3:1 ratio to receive ciraparantag or placebo, which was administered three or four hours after last dose of the anticoagulant. Ciraparantag was administered as a single intravenous infusion over 10 minutes, followed by serial testing of WBCT over 24 hours. Doses of ciraparantag were evaluated at 30 mg, 60 mg and 120 mg for apixaban and 30 mg, 60 mg, 120 mg and 180 mg for rivaroxaban.

ShowHide Related Items >><<
AMAG Amag Pharmaceuticals
$7.27 /

+0.21 (+2.97%)

AMAG Amag Pharmaceuticals
$7.27 /

+0.21 (+2.97%)

05/12/20 H.C. Wainwright
Amag Pharmaceuticals price target raised to $10 from $9 at H.C. Wainwright
05/11/20 Piper Sandler
Amag shares to continue to see pressure from headwinds, says Piper Sandler
04/17/20 H.C. Wainwright
Amag Pharmaceuticals price target lowered to $9 from $12 at H.C. Wainwright
03/04/20 Piper Sandler
Amag Pharmaceuticals price target lowered to $7 from $9 at Piper Sandler
AMAG Amag Pharmaceuticals
$7.27 /

+0.21 (+2.97%)

Hot Stocks
Takeda provides updates on Pharmacokinetic-guided Prophylaxis studies » 16:24
07/12/20
07/12
16:24
07/12/20
16:24
TAK

Takeda Pharmaceutical

$17.26 /

-0.02 (-0.12%)

Takeda Pharmaceutical…

Takeda Pharmaceutical announced that 13 abstracts are being presented from the company's Hematology portfolio and pipeline at the International Society on Thrombosis and Haemostasis 2020 Virtual Congress. Among the data, Takeda spotlighted four abstracts to highlight its commitment to advancing personalized care through pharmacokinetic-guided prophylaxis in people living with hemophilia or von Willebrand Disease - including scientific updates in patients with hemophilia A from the Phase 3 PROPEL and Phase 3b CONTINUATION studies investigating potential benefits of personalized TAK-660 prophylaxis. Two population studies into the PK/pharmacodynamic profiles of recombinant von Willebrand factor, which provide data to assist in the optimization of rVWF personalized dosing strategies, were also presented. Data from a post-hoc analysis of the Phase III PROPEL trial evaluating the efficacy and target joint resolution with PK-guided TAK-660 prophylaxis in patients with hemophilia A show that targeting 8%-12% versus 1%-3% FVIII trough levels was associated with reduced bleeding into TJs, reduced annualized bleed rate irrespective of baseline TJ status, and TJ resolution within the first 6 months. An analysis exploring the potential benefits of personalized TAK-660 prophylaxis evaluated data on extended fixed dose or PK-tailored dosing from two respective studies - the Phase IIIb CONTINUATION and the Phase III PROPEL studies. Results from the two studies support the feasibility and efficacy of personalized TAK-660 prophylaxis by extending the fixed dose interval or by targeting elevated FVIII levels with PK-tailored dosing. On the other hand, for patients with VWD, rVWF replacement therapy corrects VWF activity, as measured mostly by VWF:Ristocetin Cofactor, and leads consecutively to an endogenous increase of FVIII activity to hemostatically effective levels. The goals of Takeda's PK studies in VWD are to understand the effects of rVWF dosing on VWF:RCo and FVIII activities and thus help patients living with VWD and their physicians achieve agreed treatment goals. Results from the modelling supported the feasibility of this PK/PD population model for describing VWF:RCo and FVIII activity in rVWF-treated patients with different VWD types, which could assist in the optimization of rVWF personalized dosing strategies. The population PK/PD models aimed to characterize VWF:RCo and endogenous FVIII activity-time curves following administration of rVWF, based on data from Phase I and Phase III studies. Results from the modelling supported the feasibility of this PK population model for describing activity-time profiles of small, medium and large multimers following rVWF dosing on VWF:RCo. The findings increase understanding of the effects of rVWF dosing on VWF:RCo and FVIII activities which could potentially optimize treatment regimens for individual patient needs. In addition to data from the four aforementioned studies, Takeda presented real-world evidence of extended half-life prophylaxis with TAK-660, which showed that switching from standard half-life FVIII to TAK-660 given at lower frequency and with weekly consumption resulted in reduced ABRs.vii Results were also presented from the American Thrombosis and Hemostasis Network ATHN 2: Factor Switching Study, which show that for the 52 participants in the study who switched from any FVIII concentrate to TAK-660, no new inhibitors were detected after 50 exposure days or 12 months. A further seven studies presented included a retrospective chart review of gastrointestinal bleeding in VWD, and pre-clinical and post-marketing updates on susoctocog alfa for the treatment of acquired hemophilia.

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$17.26 /

-0.02 (-0.12%)

TAK Takeda Pharmaceutical
$17.26 /

-0.02 (-0.12%)

06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
TAK Takeda Pharmaceutical
$17.26 /

-0.02 (-0.12%)

TAK Takeda Pharmaceutical
$17.26 /

-0.02 (-0.12%)

TAK Takeda Pharmaceutical
$17.26 /

-0.02 (-0.12%)

Hot Stocks
Gilat to file counterclaims seeking merger enforcement, monetary damages payment » 16:14
07/12/20
07/12
16:14
07/12/20
16:14
GILT

Gilat Satellite

$5.10 /

-0.01 (-0.20%)

Gilat Satellite announced…

Gilat Satellite announced that further to its announcement of July 8, 2020, it was notified on July 11, 2020 that an amended complaint was filed by Comtech Telecommunications and its subsidiary, Convoy, against Gilat in the Court of Chancery of the State of Delaware. The amended complaint seeks an additional declaratory judgment that Gilat has suffered a "Material Adverse Effect" as defined in the Merger Agreement, as a result of the COVID-19 pandemic and, as a consequence, Comtech is not required to consummate the merger because certain closing conditions of the Merger Agreement cannot be satisfied. Gilat said it strongly rejects all such allegations and believes that no Material Adverse Effect under the Merger Agreement has occurred and that Comtech's complaint is nothing more than an effort to avoid its clear contractual obligation to acquire Gilat, due to Comtech's own rapidly deteriorating performance. "Comtech's continuous willful breaches have resulted and are continuing to result in significant monetary damages to Gilat and its shareholders, and are expected to amount to hundreds of millions of dollars if the merger is not consummated," Gilat added. "While Gilat has not interfered or taken any action to interfere with Comtech's pending application with the Russian Federal Anti-Monopoly Service or otherwise breached the Merger Agreement, Gilat believes that Comtech has willfully breached its obligations under the Merger Agreement so as to attempt to ensure that FAS approval is not timely obtained and Comtech will not be required to consummate the merger. Gilat intends to vigorously defend its position in connection with the claims raised by Comtech and all related matters." Gilat also intends to file a counter claim against Comtech seeking, among other things, a declaration that Comtech cannot terminate the Merger Agreement and, if the merger is not consummated, Comtech should pay Gilat monetary damages "for all losses that Gilat and its shareholders and option holders have suffered as a result of Comtech's willful breaches of the Merger Agreement, which Gilat will assert amount to hundreds of millions of dollars."

ShowHide Related Items >><<
GILT Gilat Satellite
$5.10 /

-0.01 (-0.20%)

GILT Gilat Satellite
$5.10 /

-0.01 (-0.20%)

GILT Gilat Satellite
$5.10 /

-0.01 (-0.20%)

GILT Gilat Satellite
$5.10 /

-0.01 (-0.20%)

On The Fly
Opening Day: Cancer 'killer' Nkarta soars after coming public » 08:57
07/12/20
07/12
08:57
07/12/20
08:57
BLCT

BlueCity

$24.39 /

-1.59 (-6.12%)

, NKTX

Nkarta

$47.46 /

+ (+0.00%)

, QH

Quhuo

$12.62 /

+ (+0.00%)

, PSTX

Poseida Therapeutics

$15.60 /

+ (+0.00%)

, RXT

Rackspace Technology

$0.00 /

+ (+0.00%)

, NCNO

nCino

$0.00 /

+ (+0.00%)

, GOCO

GoHealth

$0.00 /

+ (+0.00%)

China's biggest gay…

Open Full Text

ShowHide Related Items >><<
  • 15
    Jul
  • 15
    Jul
  • 08
    Jul
  • 10
    Jul
  • 10
    Jul
RXT Rackspace Technology
$0.00 /

+ (+0.00%)

NKTX Nkarta
$47.46 /

+ (+0.00%)

Conference/Events
Society for Pediatric Dermatology to hold virtual meeting » 05:55
07/12/20
07/12
05:55
07/12/20
05:55
ABEO

Abeona Therapeutics

$3.01 /

-0.34 (-10.15%)

, AMGN

Amgen

$249.23 /

-2.03 (-0.81%)

, DRMT

Dermavant

$0.00 /

+ (+0.00%)

, NVS

Novartis

$87.02 /

-0.3 (-0.34%)

, PFE

Pfizer

$33.84 /

+0.39 (+1.17%)

, SNY

Sanofi

$50.32 /

-0.24 (-0.47%)

, VRCA

Verrica Pharmaceuticals

$9.51 /

+0.75 (+8.56%)

45th Annual Virtual…

45th Annual Virtual Meeting: SPD2020 will be held on July 10-12. Webcast Link

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$9.51 /

+0.75 (+8.56%)

SNY Sanofi
$50.32 /

-0.24 (-0.47%)

PFE Pfizer
$33.84 /

+0.39 (+1.17%)

NVS Novartis
$87.02 /

-0.3 (-0.34%)

DRMT Dermavant
$0.00 /

+ (+0.00%)

AMGN Amgen
$249.23 /

-2.03 (-0.81%)

ABEO Abeona Therapeutics
$3.01 /

-0.34 (-10.15%)

ABEO Abeona Therapeutics
$3.01 /

-0.34 (-10.15%)

06/05/20 Cantor Fitzgerald
Abeona could trade higher on Lysogene clinical hold, says Cantor Fitzgerald
05/08/20 Jefferies
Abeona 'one of most underappreciated' in late-stage gene therapy, says Jefferies
12/30/19 H.C. Wainwright
Abeona Therapeutics price target lowered to $11 from $15 at H.C. Wainwright
12/20/19 Cantor Fitzgerald
Abeona financing to lessen takeover chartter, says Cantor Fitzgerald
AMGN Amgen
$249.23 /

-2.03 (-0.81%)

07/02/20 Citi
Citi sees 'considerable amount of investor interest' coming back to Amgen
07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Mizuho
Amgen patent win worth $5-$12 per share, says Mizuho
07/01/20 Goldman Sachs
Court ruling removes overhang for Amgen, says Goldman Sachs
DRMT Dermavant
$0.00 /

+ (+0.00%)

NVS Novartis
$87.02 /

-0.3 (-0.34%)

07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
PFE Pfizer
$33.84 /

+0.39 (+1.17%)

07/08/20 Piper Sandler
Opko Health price target raised to $6 from $4 at Piper Sandler
07/08/20 Argus
Pfizer positioned for stronger revenue growth in 2021 and beyond, says Argus
07/07/20 Needham
Vaxcyte initiated with a Buy at Needham
07/02/20 B. Riley FBR
Novavax should be bought on weakness from Pfizer data, says B. Riley FBR
SNY Sanofi
$50.32 /

-0.24 (-0.47%)

07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
07/01/20 Roth Capital
Applied Genetic may attract Sanofi takeover interest, says Roth Capital
06/26/20 SunTrust
Translate Bio initiated with a Buy at SunTrust
VRCA Verrica Pharmaceuticals
$9.51 /

+0.75 (+8.56%)

06/30/20 H.C. Wainwright
Verrica Pharmaceuticals price target lowered to $18 from $24 at H.C. Wainwright
06/24/20 Northland
Verrica Pharmaceuticals initiated with an Outperform at Northland
03/24/20
Fly Intel: Top five analyst initiations
03/24/20 Needham
Verrica Pharmaceuticals initiated with a Buy at Needham
VRCA Verrica Pharmaceuticals
$9.51 /

+0.75 (+8.56%)

SNY Sanofi
$50.32 /

-0.24 (-0.47%)

PFE Pfizer
$33.84 /

+0.39 (+1.17%)

NVS Novartis
$87.02 /

-0.3 (-0.34%)

AMGN Amgen
$249.23 /

-2.03 (-0.81%)

ABEO Abeona Therapeutics
$3.01 /

-0.34 (-10.15%)

  • 20
    Dec
SNY Sanofi
$50.32 /

-0.24 (-0.47%)

PFE Pfizer
$33.84 /

+0.39 (+1.17%)

NVS Novartis
$87.02 /

-0.3 (-0.34%)

AMGN Amgen
$249.23 /

-2.03 (-0.81%)

VRCA Verrica Pharmaceuticals
$9.51 /

+0.75 (+8.56%)

SNY Sanofi
$50.32 /

-0.24 (-0.47%)

PFE Pfizer
$33.84 /

+0.39 (+1.17%)

NVS Novartis
$87.02 /

-0.3 (-0.34%)

AMGN Amgen
$249.23 /

-2.03 (-0.81%)

SNY Sanofi
$50.32 /

-0.24 (-0.47%)

PFE Pfizer
$33.84 /

+0.39 (+1.17%)

NVS Novartis
$87.02 /

-0.3 (-0.34%)

AMGN Amgen
$249.23 /

-2.03 (-0.81%)

Periodicals
ASML powering past pandemic, Barron's says » 09:47
07/11/20
07/11
09:47
07/11/20
09:47
ASML

ASML

$396.30 /

+1.605 (+0.41%)

ASML a leading…

ASML a leading manufacturer of lithography machines used by major semiconductor makers to print ever-denser circuits, but the company issued a profit warning at the end of March, after completion of the installation of new equipment around the world was delayed by the pandemic, with demand for chips in cars also plunging and ASML then cutting first-quarter guidance, Rupert Steiner writes in his week's edition of Barron's. However, shares have since bounced back on strong demand, as sheltering-at-home workers turned to the cloud for storage and bought chip-intensive laptops, the author notes, adding that the stock could still rise further. Reference Link

ShowHide Related Items >><<
ASML ASML
$396.30 /

+1.605 (+0.41%)

ASML ASML
$396.30 /

+1.605 (+0.41%)

07/10/20 JPMorgan
ASML price target raised to EUR 408 from EUR 280 at JPMorgan
07/10/20 Morgan Stanley
ASML price target raised to EUR 380 from EUR 275 at Morgan Stanley
07/09/20 Wells Fargo
ASML price target raised to $430 from $410 at Wells Fargo
06/17/20 Evercore ISI
ASML price target raised to EUR 375 from EUR 325 at Evercore ISI
ASML ASML
$396.30 /

+1.605 (+0.41%)

ASML ASML
$396.30 /

+1.605 (+0.41%)

ASML ASML
$396.30 /

+1.605 (+0.41%)

Periodicals
Facebook stock remains resilient amid controversy, Barron's says » 09:44
07/11/20
07/11
09:44
07/11/20
09:44
SBUX

Starbucks

$74.29 /

+0.69 (+0.94%)

, UL

Unilever

$54.23 /

+0.535 (+1.00%)

, KO

Coca-Cola

$45.15 /

+1.23 (+2.80%)

, FB

Facebook

$245.01 /

+0.35 (+0.14%)

In the wake of…

In the wake of Facebook's (FB) first big scandal in 2018, Barron's labeled the company a sin stock - controversial but still full of upside, and now Facebook finds itself in the middle of a global boycott from 1,000 advertisers, brought to task by a coalition of civil-rights groups that cite hate speech and voter suppression that appear on its platform, Max Cherney writes in this week's edition of Barron's. While most stocks would crater under that kind of pressure, Facebook is well insulated from advertiser defections, even with big brands like Coca-Cola (KO), Unilever (UL) and Starbucks (SBUX) pausing their spending given its 8M customers, mostly small and medium-sized businesses buying adds, the author notes. Reference Link

ShowHide Related Items >><<
UL Unilever
$54.23 /

+0.535 (+1.00%)

SBUX Starbucks
$74.29 /

+0.69 (+0.94%)

KO Coca-Cola
$45.15 /

+1.23 (+2.80%)

FB Facebook
$245.01 /

+0.35 (+0.14%)

SBUX Starbucks
$74.29 /

+0.69 (+0.94%)

06/24/20 JPMorgan
Starbucks price target raised to $78 from $73 at JPMorgan
06/15/20
Fly Intel: Top five analyst initiations
06/15/20 Atlantic Equities
Starbucks initiated with an Overweight at Atlantic Equities
06/11/20
Fly Intel: Top five analyst downgrades
UL Unilever
$54.23 /

+0.535 (+1.00%)

07/07/20 Bryan Garnier
Unilever downgraded to Neutral from Buy at Bryan Garnier
07/06/20 RBC Capital
Unilever price target raised to EUR 34 from EUR 33 at RBC Capital
06/29/20 Barclays
Unilever price target raised to EUR 43.70 from EUR 43.10 at Barclays
06/29/20
Fly Intel: Top five analyst downgrades
KO Coca-Cola
$45.15 /

+1.23 (+2.80%)

06/17/20 Jefferies
Nestle home-office water business would be a fit for Primo Water, says Jefferies
05/28/20 Credit Suisse
Boston Beer downgraded to Neutral on valuation at Credit Suisse
05/18/20 Guggenheim
Guggenheim raises PepsiCo to 'Best Idea' in Food and Beverage, ups target
05/11/20 Citi
Monster Beverage downgraded to Neutral from Buy at Cit
FB Facebook
$245.01 /

+0.35 (+0.14%)

07/09/20 Wedbush
Pinterest price target raised to $31 from $26 at Wedbush
07/07/20 BofA
Potential U.S. ban of TikTok could be tailwind to Snap engagement, says BofA
07/01/20 Monness Crespi
Facebook has opportunity to emerge from crisis stronger, says Monness Crespi
07/01/20 Goldman Sachs
Facebook checks show limited impact from ad boycott, says Goldman Sachs
SBUX Starbucks
$74.29 /

+0.69 (+0.94%)

KO Coca-Cola
$45.15 /

+1.23 (+2.80%)

FB Facebook
$245.01 /

+0.35 (+0.14%)

UL Unilever
$54.23 /

+0.535 (+1.00%)

SBUX Starbucks
$74.29 /

+0.69 (+0.94%)

KO Coca-Cola
$45.15 /

+1.23 (+2.80%)

FB Facebook
$245.01 /

+0.35 (+0.14%)

UL Unilever
$54.23 /

+0.535 (+1.00%)

SBUX Starbucks
$74.29 /

+0.69 (+0.94%)

FB Facebook
$245.01 /

+0.35 (+0.14%)

SBUX Starbucks
$74.29 /

+0.69 (+0.94%)

KO Coca-Cola
$45.15 /

+1.23 (+2.80%)

FB Facebook
$245.01 /

+0.35 (+0.14%)

Periodicals
Nordstrom may be worth the wait, Barron's says » 09:27
07/11/20
07/11
09:27
07/11/20
09:27
JWN

Nordstrom

$15.75 /

+0.46 (+3.01%)

, REAL

RealReal

$13.77 /

-0.51 (-3.57%)

, YETI

Yeti

$41.79 /

-0.08 (-0.19%)

, NKE

Nike

$97.98 /

+0.98 (+1.01%)

, LULU

Lululemon

$314.47 /

+0.02 (+0.01%)

Retail sales plunged in…

Retail sales plunged in March and April, and though sales have been rebounding-May saw the largest month-over-month increase in retail sales on record-retailers can't depend on pent-up demand and store reopenings to keep sales rising, Teresa Rivas writes in this week's edition of Barron's. Lululemon (LULU) and Nike (NKE) have been among the most prominent retailers to negotiate that transition, but they are not alone, the author notes. Yeti (YETI) is one of those, with its strategy paying off and shares rising 38% during the first quarter. The RealReal (REAL) hasn't performed nearly as well as Yeti, but the company's online consultations for its customers simulating an in-store experience could be beneficial from a cost and time perspective, the publication adds. While Nordstrom (JWN) looks even worse off than RealReal, its earnings per share have fallen less than its peers over the part year and it could eventually be worth the wait for those with patience, Rivas contends. Reference Link

ShowHide Related Items >><<
YETI Yeti
$41.79 /

-0.08 (-0.19%)

REAL RealReal
$13.77 /

-0.51 (-3.57%)

NKE Nike
$97.98 /

+0.98 (+1.01%)

LULU Lululemon
$314.47 /

+0.02 (+0.01%)

JWN Nordstrom
$15.75 /

+0.46 (+3.01%)

JWN Nordstrom
$15.75 /

+0.46 (+3.01%)

05/14/20 KeyBanc
Farfetch, Nordstrom, Revolve could be impacted by Amazon offering, says KeyBanc
05/07/20 Deutsche Bank
Nordstrom price target lowered to $18 from $35 at Deutsche Bank
04/30/20 Wedbush
Nordstrom price target lowered to $20 from $36 at Wedbush
03/27/20 Cleveland Research
Nordstrom downgraded at Cleveland Research, says QTD net sales have slowed
REAL RealReal
$13.77 /

-0.51 (-3.57%)

07/10/20 B. Riley FBR
RealReal price target raised to $13 from $7 at B. Riley FBR
06/10/20 Nomura Instinet
RealReal price target raised to $18 from $17 at Nomura Instinet
06/09/20
Fly Intel: Top five analyst initiations
06/09/20 Nomura Instinet
RealReal price target raised to $17 from $14 at Nomura Instinet
YETI Yeti
$41.79 /

-0.08 (-0.19%)

07/07/20
Fly Intel: Top five analyst downgrades
07/07/20 Goldman Sachs
Yeti downgraded to Neutral from Buy at Goldman Sachs
06/23/20 Piper Sandler
Yeti price target raised to $47 from $35 at Piper Sandler
06/10/20 Cowen
Yeti price target raised to $41 from $31 at Cowen
NKE Nike
$97.98 /

+0.98 (+1.01%)

06/26/20 Morgan Stanley
Market understands Nike's near-term challenges, says Morgan Stanley
06/26/20 Credit Suisse
Nike price target lowered to $111 from $114 at Credit Suisse
06/26/20 UBS
Nike price target raised to $127 from $122 at UBS
06/26/20 Citi
Nike disappointments offset by quarter-to-date performance, says Citi
LULU Lululemon
$314.47 /

+0.02 (+0.01%)

07/09/20 Barclays
'Surprise' Lululemon sale may pressure shares, says Barclays
07/09/20 Barclays
Lululemon started warehouse sale online today, says Barclays
06/30/20 Morgan Stanley
Lululemon boosted competitive advantage with Mirror deal, says Morgan Stanley
06/30/20 MKM Partners
Lululemon's Mirror deal 'highly attractive and synergistic', says MKM Partners
YETI Yeti
$41.79 /

-0.08 (-0.19%)

REAL RealReal
$13.77 /

-0.51 (-3.57%)

NKE Nike
$97.98 /

+0.98 (+1.01%)

LULU Lululemon
$314.47 /

+0.02 (+0.01%)

JWN Nordstrom
$15.75 /

+0.46 (+3.01%)

  • 28
    May
  • 11
    May
  • 17
    Feb
  • 13
    Dec
  • 07
    Nov
YETI Yeti
$41.79 /

-0.08 (-0.19%)

NKE Nike
$97.98 /

+0.98 (+1.01%)

LULU Lululemon
$314.47 /

+0.02 (+0.01%)

JWN Nordstrom
$15.75 /

+0.46 (+3.01%)

YETI Yeti
$41.79 /

-0.08 (-0.19%)

REAL RealReal
$13.77 /

-0.51 (-3.57%)

NKE Nike
$97.98 /

+0.98 (+1.01%)

LULU Lululemon
$314.47 /

+0.02 (+0.01%)

JWN Nordstrom
$15.75 /

+0.46 (+3.01%)

REAL RealReal
$13.77 /

-0.51 (-3.57%)

NKE Nike
$97.98 /

+0.98 (+1.01%)

LULU Lululemon
$314.47 /

+0.02 (+0.01%)

JWN Nordstrom
$15.75 /

+0.46 (+3.01%)

Periodicals
Nokia to gain from 5G spending, stock still 'cheap,' Barron's says » 09:18
07/11/20
07/11
09:18
07/11/20
09:18
ERIC

Ericsson

$9.42 /

+0.045 (+0.48%)

, NOK

Nokia

$4.13 /

-0.045 (-1.08%)

Once the most valuable…

Once the most valuable European stock, with a market cap that touched $300B, shares of Nokia (NOK) have fallen more than 90% since 2000, to $24B, Eric Savitz writes in this week's edition of Barron's. Yet there are reasons to think the worst is over given the speedy wireless standard known as 5G and as the company finds itself in favor with the Trump administration, which has expressed interest in bolstering both Nokia and Ericsson (ERIC) in their competition against Huawei, the author notes. Reference Link

ShowHide Related Items >><<
NOK Nokia
$4.13 /

-0.045 (-1.08%)

ERIC Ericsson
$9.42 /

+0.045 (+0.48%)

ERIC Ericsson
$9.42 /

+0.045 (+0.48%)

04/17/20 Credit Suisse
Ericsson price target raised to SEK 98 from SEK 97 at Credit Suisse
03/30/20 BofA
US 1 List changes at BofA
03/30/20 Cowen
Ericsson upgraded to Outperform from Market Perform at Cowen
03/27/20 Raymond James
Raymond James upgrades Ericsson with networking an essential service
NOK Nokia
$4.13 /

-0.045 (-1.08%)

07/08/20 JPMorgan
Nokia downgraded to Neutral from Overweight at JPMorgan
07/06/20 Rosenblatt
Samsung on track to replace Nokia as 5G RAN supplier at Verizon, says Rosenblatt
06/25/20 Deutsche Bank
Nokia price target raised to EUR 4.80 from EUR 4 at Deutsche Bank
06/01/20 JPMorgan
JPMorgan upgrades Nokia to Overweight with 5G cycle 'just starting'
NOK Nokia
$4.13 /

-0.045 (-1.08%)

ERIC Ericsson
$9.42 /

+0.045 (+0.48%)

NOK Nokia
$4.13 /

-0.045 (-1.08%)

ERIC Ericsson
$9.42 /

+0.045 (+0.48%)

NOK Nokia
$4.13 /

-0.045 (-1.08%)

ERIC Ericsson
$9.42 /

+0.045 (+0.48%)

NOK Nokia
$4.13 /

-0.045 (-1.08%)

ERIC Ericsson
$9.42 /

+0.045 (+0.48%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.